NCT00609544
Withdrawn
Phase 2
A Multi-Center, Double-Blind, Placebo-Controlled Safety and Preliminary Efficacy Study of IL-1 Trap (Rilonacept) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Overview
- Phase
- Phase 2
- Intervention
- Rilonacept
- Conditions
- Chronic Kidney Disease
- Sponsor
- Regeneron Pharmaceuticals
- Primary Endpoint
- Change in blood hemoglobin concentration.
- Status
- Withdrawn
- Last Updated
- 15 years ago
Overview
Brief Summary
Anemia of inflammation is a common complication in patients with chronic kidney disease (CKD). Patients with CKD and anemia of inflammation also exhibit decreased response to erythropoietic agents, even in the presence of adequate iron stores. This decreased responsiveness is associated with increased levels of proinflammatory cytokines. Rilonacept is being developed for the treatment of inflammatory disorders.
This is a clinical research study to determine the safety and effectiveness of rilonacept for the treatment of anemia in inflamed patients with CKD who are not yet on dialysis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female greater than 18 years of age
- •Chronic Kidney Disease (CKD) not yet requiring renal replacement therapy (pre-dialysis patients)
- •Not expected to require dialysis during duration of the study
- •Adequate laboratory values
- •If on rHuEPO therapy, the dose must be stable
Exclusion Criteria
- •Persistent chronic or active infections
- •Intravenous (IV) iron administration within 12 weeks prior to the Screening Visit
- •Known history of severe uncontrolled hyperparathyroidism
- •Prior recipient or scheduled to receive a kidney transplant during the study
- •Abnormal laboratory values
- •Unstable angina or myocardial infarction within the past 6 months prior to the Screening Visit
- •Uncontrolled hypertension
- •Coronary disease diagnosed in the 3 months prior to the Screening Visit
- •Severe Congestive Heart Failure
- •History of HIV
Arms & Interventions
1
Intervention: Rilonacept
2
Intervention: Rilonacept
Outcomes
Primary Outcomes
Change in blood hemoglobin concentration.
Time Frame: Baseline to Week 12
Similar Trials
Completed
Not Applicable
Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.Cardiovascular DiseasesChronic Kidney DiseaseNCT02987465Cambridge University Hospitals NHS Foundation Trust29
Completed
Phase 2
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 InhibitionChronic Kidney DiseasesInflammationNCT03926117Novo Nordisk A/S264
Completed
Phase 3
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring DialysisAnemia in Chronic Kidney Disease in Non-dialysis PatientsNCT01887600Astellas Pharma Europe B.V.594
Terminated
Phase 2
A Safety Study of Pentoxifylline for the Treatment of AnemiaEnd Stage Renal DiseaseNCT01102218Fresenius Medical Care North America48
Completed
Phase 2
Alkali Therapy in Chronic Kidney DiseaseChronic Kidney DiseaseMetabolic AcidosisNCT01452412Albert Einstein College of Medicine149